These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843 [Abstract] [Full Text] [Related]
3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R. J Invasive Cardiol; 2003 Jun 11; 15(6):319-23. PubMed ID: 12777670 [Abstract] [Full Text] [Related]
4. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A. Thromb Haemost; 1998 Dec 11; 80(6):994-1001. PubMed ID: 9869173 [Abstract] [Full Text] [Related]
5. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. Nguyen N, Salib H, Mascarenhas DA. J Invasive Cardiol; 2001 Jan 11; 13(1):56-8. PubMed ID: 11146690 [Abstract] [Full Text] [Related]
6. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Circulation; 1997 Feb 18; 95(4):809-13. PubMed ID: 9054735 [Abstract] [Full Text] [Related]
7. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C. Am J Cardiol; 1999 Sep 01; 84(5):519-24. PubMed ID: 10482148 [Abstract] [Full Text] [Related]
8. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L. Am J Cardiol; 2004 Feb 15; 93(4):453-5. PubMed ID: 14969621 [Abstract] [Full Text] [Related]
10. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Jubelirer SJ, Koenig BA, Bates MC. Am J Hematol; 1999 Jul 15; 61(3):205-8. PubMed ID: 10398314 [Abstract] [Full Text] [Related]
11. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Joseph T, Marco J, Gregorini L. Clin Cardiol; 1998 Nov 15; 21(11):851-2. PubMed ID: 9825202 [Abstract] [Full Text] [Related]
12. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. Coto H. J Invasive Cardiol; 2000 Oct 15; 12(10):528-31. PubMed ID: 11022214 [Abstract] [Full Text] [Related]
13. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. J Am Coll Cardiol; 1998 Aug 15; 32(2):311-9. PubMed ID: 9708455 [Abstract] [Full Text] [Related]
14. ABCIXIMAB: a new antiaggregant used in angioplasty. Genetta TB, Mauro VF. Ann Pharmacother; 1996 Mar 15; 30(3):251-7. PubMed ID: 8833561 [Abstract] [Full Text] [Related]
15. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro. Kozak M, Dovc T, Rozman P, Blinc A. Wien Klin Wochenschr; 2000 Feb 11; 112(3):138-41. PubMed ID: 10729966 [Abstract] [Full Text] [Related]
16. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425 [Abstract] [Full Text] [Related]
17. Thrombocytopenia associated with c7E3 Fab (abciximab). Schell DA, Ganti AK, Levitt R, Potti A. Ann Hematol; 2002 Feb 21; 81(2):76-9. PubMed ID: 11907786 [Abstract] [Full Text] [Related]
18. Acute severe thrombocytopenia after treatment with ReoPro (abciximab). Butler R, Hubner PJ. Heart; 2000 Apr 21; 83(4):E5. PubMed ID: 10722557 [Abstract] [Full Text] [Related]
19. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Am Heart J; 2000 Aug 21; 140(2):206-11. PubMed ID: 10925331 [Abstract] [Full Text] [Related]
20. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Cochrane Database Syst Rev; 2014 Mar 08; (3):CD005208. PubMed ID: 24609741 [Abstract] [Full Text] [Related] Page: [Next] [New Search]